|
| 37085425 | Bone Biomarkers and Subsequent Survival in Men with Hormone-sensitive Prostate Cancer: Results from the SWOG S1216 Phase 3 Trial of Androgen Deprivation Therapy with or Without Orteronel. | Eur Urol | 2024 |
| 35984996 | EphrinB2 Inhibition and Pembrolizumab in Metastatic Urothelial Carcinoma. | J Clin Oncol | 2023 |
| 37526936 | Race and Treatment Outcomes in Patients With Metastatic Castration-Sensitive Prostate Cancer: A Secondary Analysis of the SWOG 1216 Phase 3 Trial. | JAMA Netw Open | 2023 |
| 37575160 | EphrinB2: Expression of a novel potential target in renal cell carcinoma. | Indian J Urol | 2023 |
| 37087309 | Cell-free DNA Methylation as a Predictive Biomarker of Response to Neoadjuvant Chemotherapy for Patients with Muscle-invasive Bladder Cancer in SWOG S1314. | Eur Urol Oncol | 2023 |
| 37058234 | Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials. | Clin Cancer Res | 2023 |
| 37080171 | Radiogenomic Associations Clear Cell Renal Cell Carcinoma: An Exploratory Study. | Oncology | 2023 |
| 36746967 | Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers. | Nat Commun | 2023 |
| 36928921 | A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy. | Clin Cancer Res | 2023 |
| 36240478 | FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on FGFR1/3 mRNA Expression. | J Clin Oncol | 2023 |
| 34454823 | Albumin levels predict prognosis in advanced renal cell carcinoma treated with tyrosine kinase inhibitors: a systematic review and meta-analysis. | Urol Oncol | 2022 |
| 35575959 | Integration of Liquid Biopsies in Clinical Management of Metastatic Prostate Cancer. | Curr Oncol Rep | 2022 |
| 35688679 | A Phase II, Single-arm Trial of Sunitinib and Erlotinib in Advanced Renal Cell Carcinoma. | Clin Genitourin Cancer | 2022 |
| 35446628 | Orteronel for Metastatic Hormone-Sensitive Prostate Cancer: A Multicenter, Randomized, Open-Label Phase III Trial (SWOG-1216). | J Clin Oncol | 2022 |
| 36333289 | Collaborative study from the Bladder Cancer Advocacy Network for the genomic analysis of metastatic urothelial cancer. | Nat Commun | 2022 |
| 36319116 | Oligometastatic Prostate Cancer: Current Status and Future Challenges. | J Nucl Med | 2022 |
| 35247908 | Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials. | Clin Cancer Res | 2022 |
| 35151428 | Bladder cancer: from a therapeutic wilderness to so many options; a guide to practice in a changing landscape. | Ann Oncol | 2022 |
| 35269713 | Non-Invasive Profiling of Advanced Prostate Cancer via Multi-Parametric Liquid Biopsy and Radiomic Analysis. | Int J Mol Sci | 2022 |
| 34994657 | Management Trends and Outcomes of Patients Undergoing Radical Cystectomy for Urothelial Carcinoma of the Bladder: Evolution of the University of Southern California Experience over 3,347 Cases. | J Urol | 2022 |
| 35168844 | Health-related Quality of Life of Patients with Locally Advanced or Metastatic Urothelial Cancer Treated with Enfortumab Vedotin after Platinum and PD-1/PD-L1 Inhibitor Therapy: Results from Cohort 1 of the Phase 2 EV-201 Clinical Trial. | Eur Urol | 2022 |
| 34782263 | Infigratinib in Early-Line and Salvage Therapy for FGFR3-Altered Metastatic Urothelial Carcinoma. | Clin Genitourin Cancer | 2022 |
| 32123315 | Phase 2 trial of monoamine oxidase inhibitor phenelzine in biochemical recurrent prostate cancer. | Prostate Cancer Prostatic Dis | 2021 |
| 33744812 | A randomized phase IIa study of quantified bone scan response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 dichloride alone or in combination with abiraterone acetate/prednisone or enzalutamide. | ESMO Open | 2021 |
| 33901868 | ATLAS trial of adjuvant axitinib in patients with renal cell carcinoma: subgroup analyses with focus on axitinib dosing and racial groups. | ESMO Open | 2021 |
| 33500355 | Baseline Circulating Tumor Cell Count as a Prognostic Marker of PSA Response and Disease Progression in Metastatic Castrate-Sensitive Prostate Cancer (SWOG S1216). | Clin Cancer Res | 2021 |
| 34407342 | Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma. | N Engl J Med | 2021 |
| 33991512 | Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EVâ¿¿201): a multicentre, single-arm, phase 2 trial. | Lancet Oncol | 2021 |
| 34031784 | Phase II trial of brentuximab vedotin in relapsed/refractory germ cell tumors. | Invest New Drugs | 2021 |
| 33262136 | Circulating Tumor Cell Subtypes and T-cell Populations as Prognostic Biomarkers to Combination Immunotherapy in Patients with Metastatic Genitourinary Cancer. | Clin Cancer Res | 2021 |
| 33409898 | Phase II study of the histone deacetylase inhibitor vorinostat (Suberoylanilide Hydroxamic Acid; SAHA) in recurrent or metastatic transitional cell carcinoma of the urothelium - an NCI-CTEP sponsored: California Cancer Consortium trial, NCI 6879. | Invest New Drugs | 2021 |
| 32368717 | Comparative Survival of Asian and White Metastatic Castration-Resistant Prostate Cancer Men Treated With Docetaxel. | JNCI Cancer Spectr | 2020 |
| 32031899 | EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4-Positive Solid Tumors, Including Metastatic Urothelial Carcinoma. | J Clin Oncol | 2020 |
| 32055002 | Survival outcomes and risk group validation from SWOG S0925: a randomized phase II study of cixutumumab in new metastatic hormone-sensitive prostate cancer. | Prostate Cancer Prostatic Dis | 2020 |
| 31661381 | Editorial Comment. | J Urol | 2020 |
| 32044240 | Chemoradiation for Management of Locally Recurrent or Residual Bladder Cancer: A Case Series and Review of the Literature. | Clin Genitourin Cancer | 2020 |
| 32037533 | Cancer transcriptomic profiling from rapidly enriched circulating tumor cells. | Int J Cancer | 2020 |
| 32970482 | Use of Wearable Activity Tracker in Patients With Cancer Undergoing Chemotherapy: Toward Evaluating Risk of Unplanned Health Care Encounters. | JCO Clin Cancer Inform | 2020 |
| 32847703 | Hyperphosphatemia Secondary to the Selective Fibroblast Growth Factor Receptor 1-3 Inhibitor Infigratinib (BGJ398) Is Associated with Antitumor Efficacy in Fibroblast Growth Factor Receptor 3-altered Advanced/Metastatic Urothelial Carcinoma. | Eur Urol | 2020 |
| 32366119 | Evaluating Changes in Immune Function and Bone Microenvironment During Radium-223 Treatment of Patients with Castration-Resistant Prostate Cancer. | Cancer Biother Radiopharm | 2020 |
| 32154908 | Reply to Potential underestimation of cerebrovascular events in the PROVENGE Registry for the Observation, Collection, and Evaluation of Experience Data. | Cancer | 2020 |
| 32362422 | EphrinB2 expression in prostate adenocarcinoma: Implications for targeted therapy. | Pathol Res Pract | 2020 |
| 32472319 | Safety and efficacy of CDX-014, an antibody-drug conjugate directed against T cell immunoglobulin mucin-1 in advanced renal cell carcinoma. | Invest New Drugs | 2020 |
| 32208524 | Infigratinib in upper tract urothelial carcinoma versus urothelial carcinoma of the bladder and its association with comprehensive genomic profiling and/or cell-free DNA results. | Cancer | 2020 |
| 32146152 | Programmed Death 1 and Programmed Death Ligand 1 Inhibitors in Advanced and Recurrent Urothelial Carcinoma: Meta-analysis of Single-Agent Studies. | Clin Genitourin Cancer | 2020 |
| 32111923 | Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry. | Prostate Cancer Prostatic Dis | 2020 |
| 32271672 | Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer. | J Clin Oncol | 2020 |
| 32398404 | Eligibility Criteria and Endpoints in Metastatic Renal Cell Carcinoma Trials. | Am J Clin Oncol | 2020 |
| 32194866 | Comparative prognostic implication of treatment response assessments in mCRPC: PERCIST 1.0, RECIST 1.1, and PSA response criteria. | Theranostics | 2020 |
| 32289380 | Clinical outcomes in men of diverse ethnic backgrounds with metastatic castration-resistant prostate cancer. | Ann Oncol | 2020 |